Drilldown: Medicines
Use the filters below to narrow your results.
generic:
7-Hydroxymitragynine (1) ·
Acetylfentanyl (1) ·
Alfentanil (1) ·
Butorphanol (1) ·
Carfentanil (1) ·
Codeine (2) ·
Desomorphine (1) ·
Dextropropoxyphene (1) ·
Diacetylmorphine (1) ·
Dihydrocodeine (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Kratom (1) ·
Levorphanol (1) ·
Lithium (1) ·
Meperidine (1) ·
Mitragynine (1) ·
Nalbuphine (1) ·
O-Desmethyltramadol (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Remifentanil (1) ·
Sufentanil (1) ·
Tapentadol (1) ·
Thebaine (1) ·
Tianeptine (1) ·
U-47700 (1)
brand:
None (12) ·
(multiple, generic dominant) (1) ·
Alfenta (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
Heroin (1) ·
Krokodil (1) ·
Lithobid (lithium carbonate extended-release, 300 mg and 450 mg tablets); Lithium carbonate immediate-release tablets and capsules (150/300/600 mg; multiple generics); Lithium citrate oral solution (8 mEq/5 mL, approximately equivalent to 300 mg lithium carbonate per 5 mL). (1) ·
Nubain (1) ·
Nucynta (1) ·
O-DSMT (1) ·
Opana (1) ·
Stablon (1) ·
Stadol (1) ·
Sufenta (1) ·
Talwin (1) ·
Ultiva (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
Active metabolite of tramadol; mu-opioid agonist (1) ·
Extremely potent mu-opioid receptor agonist (1) ·
Highly potent mu-opioid receptor agonist (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; fentanyl analogue (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Opioid receptor partial agonist/antagonist; toxic alkaloid (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (6) ·
Prodrug of morphine; mu-opioid receptor agonist (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Selective mu-opioid receptor agonist (1) ·
Ultra-short-acting mu-opioid agonist (1) ·
'"`UNIQ--vote-0000004A-QINU`"' (1)
starting dose:
None (29) ·
Acute mania: 300 mg PO TID (immediate-release) or 900 mg PO once daily (extended-release Lithobid); titrate based on serum levels to target 0.8-1.2 mEq/L. Maintenance: target 0.6-0.8 mEq/L. All dosing guided by serum lithium levels drawn at the 12-hour post-dose standardized trough. (1) ·
Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
fda max:
routes:
onset:
None (29) ·
30–60 min (PO) (1) ·
Oral peak plasma 1-2 hours (immediate-release); 4-6 hours (extended-release). Therapeutic antimanic effect typically evident within 5-14 days of achieving target serum levels; for acute mania, a neuroleptic or benzodiazepine is usually co-administered while lithium titration proceeds. (1)
duration:
halflife:
None (29) ·
18-36 hours at steady state; longer in elderly patients (24-60 hours) and those with renal impairment. Half-life is entirely a function of glomerular filtration rate, as lithium is exclusively renally eliminated with no hepatic metabolism.'"`UNIQ--ref-0000004C-QINU`"' (1) ·
2.5–3 hours (1)
bioavailability:
pregnancy:
Showing below up to 31 results in range #1 to #31.